Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Michael Secora Biography and Net Worth

CFO of Recursion Pharmaceuticals

Michael Secora, Ph.D., has served as our Chief Financial Officer since March 2020. Prior to joining us, Dr. Secora worked at Laurion Capital Management, as an asset manager based in New York City from July 2010 to February 2020, where he was Managing Director and Head of Capital Markets and Venture. During his time at Laurion, he developed, executed and managed fundamentally grounded investment strategies as well as built business partnerships and technological infrastructure for investing in event-driven, fundamental and macroeconomic contexts.

At Laurion Capital Management, Dr. Secora was active in venture, crossover, capital markets, public and special situations investing particularly within emerging technologies and the life sciences. Dr. Secora received his Ph.D. from Princeton University in Applied and Computational Mathematics and B.S. in Mathematics and Physics from Massachusetts Institute of Technology.

What is Michael Secora's net worth?: The estimated net worth of Michael Secora is at least $10.00 million as of April 17th, 2024. Dr. Secora owns 1,231,055 shares of Recursion Pharmaceuticals stock worth more than $9,996,167 as of April 27th. This net worth evaluation does not reflect any other assets that Dr. Secora may own. Additionally, Dr. Secora receives a salary of $524,190.00 as CFO at Recursion Pharmaceuticals. Learn More about Michael Secora's net worth.
How old is Michael Secora?: Dr. Secora is currently 41 years old. There are 2 older executives and no younger executives at Recursion Pharmaceuticals. The oldest executive at Recursion Pharmaceuticals is Ms. Tina Marriott Larson, COO & President, who is 49 years old. Learn More on Michael Secora's age.
What is Michael Secora's salary?: As the CFO of Recursion Pharmaceuticals, Inc., Dr. Secora earns $524,190.00 per year. There are 2 executives that earn more than Dr. Secora. The highest earning executive at Recursion Pharmaceuticals is Dr. Christopher C. Gibson Ph.D., Co-Founder, CEO & Director, who commands a salary of $695,180.00 per year. Learn More on Michael Secora's salary.
How do I contact Michael Secora?: The corporate mailing address for Dr. Secora and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at [email protected]. Learn More on Michael Secora's contact information.
Has Michael Secora been buying or selling shares of Recursion Pharmaceuticals?: Over the course of the past ninety days, Michael Secora has sold $175,279.92 in Recursion Pharmaceuticals stock. Most recently, Michael Secora sold 23,124 shares of the business's stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $7.58, for a transaction totalling $175,279.92. Following the completion of the sale, the chief financial officer now directly owns 1,231,055 shares of the company's stock, valued at $9,331,396.90. Learn More on Michael Secora's trading history.
Who are Recursion Pharmaceuticals' active insiders?: Recursion Pharmaceuticals' insider roster includes Blake Borgeson (Director), Terry-Ann Burrell (Director), Zavain Dar (Director), Christopher Gibson (CEO), Tina Larson (COO), Dean Li (Director), Michael Secora (CFO), and Shafique Virani (Chief Corporate Development Officer). Learn More on Recursion Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Recursion Pharmaceuticals?: In the last year, insiders at the sold shares 70 times. They sold a total of 1,443,105 shares worth more than $13,646,266.83. The most recent insider tranaction occured on April, 17th when CFO Michael Secora sold 23,124 shares worth more than $175,279.92. Insiders at Recursion Pharmaceuticals own 20.0% of the company. Learn More about insider trades at Recursion Pharmaceuticals.
Information on this page was last updated on 4/17/2024.

Michael Secora Insider Trading History at Recursion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/17/2024	Sell	23,124	$7.58	$175,279.92	1,231,055
3/13/2024	Sell	25,000	$11.03	$275,750.00	1,204,179
2/13/2024	Sell	25,000	$9.86	$246,500.00	1,173,851
1/16/2024	Sell	25,000	$10.45	$261,250.00	968,514
12/12/2023	Sell	25,000	$7.39	$184,750.00	943,514
11/14/2023	Sell	25,000	$6.32	$158,000.00	925,686
10/10/2023	Sell	25,000	$7.07	$176,750.00	900,686
9/13/2023	Sell	25,000	$8.69	$217,250.00	888,186
8/16/2023	Sell	25,000	$8.90	$222,500.00	863,186
7/18/2023	Sell	25,000	$13.63	$340,750.00	830,413
6/13/2023	Sell	25,000	$9.93	$248,250.00	805,413

Michael Secora Buying and Selling Activity at Recursion Pharmaceuticals

Recursion Pharmaceuticals Company Overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $8.12

$7.68

$8.14

50 Day Range

MA: $10.37

$7.35

$15.52

2 Week Range

Now: $8.12

$4.54

$16.75

Volume

4,391,154 shs

Average Volume

4,187,155 shs

Market Capitalization

$1.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Click For My #1 FREE Crypto for 2024

Michael Secora Biography and Net Worth

What is Michael Secora's net worth?

How old is Michael Secora?

What is Michael Secora's salary?

How do I contact Michael Secora?

Has Michael Secora been buying or selling shares of Recursion Pharmaceuticals?

Who are Recursion Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Recursion Pharmaceuticals?